Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations
Alkaptonuria (AKU) is a rare autosomal recessive disorder with incidence ranging from 1:100,000 to 1:250,000. The disorder is caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase (HGD), which results from defects in the HGD gene. This enzyme converts homogentisic acid to maleylacetoacetate and has a major role in the catabolism of phenylalanine and tyrosine. To elucidate the mutation spectrum of the HGD gene in patients with alkaptonuria from 42 patients attending the National Alkaptonuria Centre, 14 exons of the HGD gene and the intron–exon boundaries were analysed by PCR-based sequencing. A total of 34 sequence variants was observed, confirming the genetic heterogeneity of AKU. Of these mutations, 26 were missense substitutions and four splice site mutations. There were two deletions and one duplication giving rise to frame shifts and one substitution abolishing the translation termination codon (no stop). Nine of the mutations were previously unreported novel variants. Using computational approaches based on the 3D structure, these novel mutations are predicted to affect the activity of the protein complex through destabilisation of the individual protomer structure or through disruption of protomer–protomer interactions.
KeywordsAlkaptonuria Homogentisic acid Novel mutation Rare genetic disorder Sequencing
DBA is supported by a CJ Martin Fellowship from the National Health and Medical Research Council (NHMRC; GNT1072476). DEVP is funded by the Brazilian agency Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). TLB receives funding from the University of Cambridge and the Wellcome Trust.
- Davison AS, Milan AM, Hughes AT, Dutton JJ, Ranganath LR (2014) Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects. Clin Chem Lab Med. doi: 10.1515/cclm-2014-0668
- Garrod AE (1908) The Croonian lectures on inborn errors of metabolism. Lecture II. Alkaptonuria. Lancet 2:73–79Google Scholar
- La Du BN, Zannoni VG, Laster L et al (1958) The nature of the defect in tyrosine metabolism in alkaptonuria. J Biol Chem 230:251–260Google Scholar
- Zatkova A, Sedlackova T, Radvansky J et al (2011) Identification of 11 novel homogentisate 1,2 dioxygenase variants in alkaptonuria patients and establishment of a novel LOVD-based HGD mutation database. JIMD Rep 4:455–465Google Scholar